Generic · Pack · Updated Nov 11, 2026
Estradiol / norethindrone pack price what pharmacies pay, and what you should
Is my price fair?
Check the price you were quoted
Type what the pharmacy asked for estradiol / norethindrone pack and see the markup over what they pay.
A benchmark from public data, not a price offer or medical advice. Prices vary by pharmacy, insurance and discount programs.
Estradiol / norethindrone price history
What pharmacies pay for 28 tablets, weekly- Now
- $19.94
- 52-week low
- $18.98
- 52-week high
- $27.08
- A year ago
- $22.86
Why the price changed
| Effective | Before | After | Change | Reason |
|---|---|---|---|---|
| Oct 21, 2026 | $0.8020 | $0.7123 | -11.2% | pharmacies' invoice prices changed (survey) |
| Sep 23, 2026 | $0.8829 | $0.8020 | -9.2% | pharmacies' invoice prices changed (survey) |
| Aug 19, 2026 | $0.8976 | $0.8829 | -1.6% | pharmacies' invoice prices changed (survey) |
| Jul 22, 2026 | $0.8086 | $0.8976 | +11.0% | pharmacies' invoice prices changed (survey) |
| Jun 17, 2026 | $0.6906 | $0.8086 | +17.1% | pharmacies' invoice prices changed (survey) |
| May 20, 2026 | $0.6778 | $0.6906 | +1.9% | pharmacies' invoice prices changed (survey) |
| Apr 22, 2026 | $0.7588 | $0.6778 | -10.7% | pharmacies' invoice prices changed (survey) |
| Mar 18, 2026 | $0.9671 | $0.7588 | -21.5% | pharmacies' invoice prices changed (survey) |
Prices per tablet. Reasons are the ones the national survey gives: a survey rate change comes from pharmacies' own invoices; a published price change follows the maker's list price.
What people paid for estradiol / norethindrone pack
What did your pharmacy charge? It takes 30 seconds, it's anonymous - and it shows everyone which pharmacies are fair.
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
Every manufacturer and package code
2 companies sell estradiol / norethindrone pack under 5 package codes (NDCs). Pharmacies pay the same per tablet whichever maker they buy from - the national average is set for the generic as a group.
| Maker | Package codes | Per unit |
|---|---|---|
| Breckenridge Pharmaceutical, Inc. | 51991-623-28 | $0.7123 |
| Ingenus Pharmaceuticals, LLC | 50742-658-28 50742-658-84 | $0.7123 |
All 5 package codes
2 older package codes are still priced but no longer in the current FDA listing.
A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.
Questions to ask your pharmacist
- "What is your cash price, without insurance?" For low-cost generics it can be less than a copay.
- "Is a 90-day supply cheaper per tablet?" Dispensing fees are charged per fill, so fewer fills often cost less.
- "Do you match other pharmacies or accept discount cards?" Many do, if you ask.
These are questions, not advice. Never change how you take a medicine without talking to your prescriber or pharmacist.
Other estradiol / norethindrone strengths and forms
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| Pack | $0.5972 | $16.72 / 28 tablets |
| Mimvey pack | $0.5972 | $16.72 / 28 tablets |
| Lo 0.5/0.1 28 day pack | $0.7123 | $59.83 / 84 tablets |
| 1/0.5 28 day pack | $0.5972 | $50.16 / 84 tablets |
Official label & what changed
These highlights do not include all the information needed to use ESTRADIOL AND NORETHINDRONE ACETATE TABLETS safely and effectively. See full prescribing information for ESTRADIOL AND NORETHINDRONE ACETATE TABLETS.ESTRADIOL and NORETHINDRONE ACETATE tablets, for oral use Initial U.S. Approval: 1998
WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER
WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER
See full prescribing information for complete boxed warning
Estrogen Plus Progestin Therapy
● The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) (5.1)
● The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer (5.2)
● The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3)
● Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia (5.1, 5.3)
Estrogen-Alone Therapy
● There is an increased risk of endometrial cancer in a woman with a uterus who use unopposed estrogens (5.2)
● The WHI estrogen-alone substudy reported increased risks of stroke and DVT (5.1)
● The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3)
● Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia (5.2, 5.3)
Estrogen Plus Progestin Therapy
Cardiovascular Disorders and Probable Dementia
The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogen (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.5)].
The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.6)].
Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.5, 14.6)].
Breast Cancer
The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer [see Warnings and Precautions (5.2), and Clinical Studies (14.5)].
Only daily oral 0.625 mg CE and 2.5 mg MPA were studied in the estrogen plus progestin substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events, dementia and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen plus progestogen therapy, taking into account her individual risk profile.
Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
Estrogen-Alone Therapy
Endometrial Cancer
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.2)].
Cardiovascular Disorders and Probable Dementia
The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.5)].
The WHIMS estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.6)].
Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia [see Warnings and Precautions (5.1, 5.3), and Clinical Studies (14.5, 14.6)].
Only daily oral 0.625 mg CE was studied in the estrogen-alone substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen-alone products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen-alone therapy, taking into account her individual risk profile.
Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
Recent major changes (as listed on the label)
RECENT MAJOR CHANGES
Warnings and Precautions, Malignant Neoplasms (5.2) 11/2023
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Questions about estradiol / norethindrone pack
How much does estradiol / norethindrone pack cost without insurance?
Pharmacies pay about $19.94 for 28 tablets ($0.7123 per tablet) as of November 11, 2026. A fair cash price is about $33.43: that cost plus a 15% margin and a $10.50 dispensing fee. Online cost-plus pharmacies charge around $32.93 including shipping.
Is my price for estradiol / norethindrone pack fair?
Compare it with the fair cash price of $33.43 for 28 tablets. Up to about $41.79 is fair; above $66.86 is high, and worth asking the pharmacy for its cash price or trying another pharmacy. Check your quote.
Is estradiol / norethindrone pack getting more expensive?
Over the last four weeks the price pharmacies pay fell 11.2%. Over a year it fell 12.8%. See the 52-week chart.
Who makes estradiol / norethindrone pack?
2 companies: Breckenridge Pharmaceutical, Inc., Ingenus Pharmaceuticals, LLC. See every package code.
Is estradiol / norethindrone in shortage?
No shortage is reported right now. We check every day.
Has estradiol / norethindrone been recalled?
4 recalls on record. Recalls name specific lots - check yours.
What does "pharmacies pay" mean?
It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.
Talk about estradiol / norethindrone pack
No comments yet. Questions, tips, what worked for you - start the conversation.